首页> 美国卫生研究院文献>Journal of Cellular and Molecular Medicine >Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker?
【2h】

Biomarkers for early diagnosis of Alzheimer disease: ‘ALZheimer ASsociated gene’– a new blood biomarker?

机译:早期诊断阿尔茨海默氏病的生物标志物: ALZheimer关联基因 —一种新的血液生物标志物?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Simple, non-invasive tests for an early detection of degenerative dementia by use of biomarkers are urgently required. However, up to the present, no validated extracerebral diagnostic markers (plasma/serum, platelets, urine, connective tissue) for the early diagnosis of Alzheimer disease (AD) are available. In disease stages with evident cognitive disturbances, the clinical diagnosis of probable AD is made with around 90% accuracy using modern clinical, neuropsychological and imaging methods. Diagnostic sensitivity and specificity even in early disease stages are improved by CSF markers, in particular combined tau and amyloid β peptides (Aβ) and plasma markers (e.g. Aβ-42/Aβ-40 ratio). Recently, a novel gene/protein – ALZAS (ALZheimer ASsociated protein) – with a 79 amino acid sequence, containing the amyloid β-42 fragment (Aβ-42), the amyloid precursor protein (APP) transmembrane signal and a 12 amino acid C-terminal, not present in any other known APP alleles, has been discovered on chromosome 21 within the APP region. Reverse transcriptase-PCR revealed the expression of the transcript of this protein in the cortex and hippocampal regions as well as in lymphocytes of human AD patients. The expression of ALZAS is mirrored by a specific autoimmune response in AD patients, directed against the ct-12 end of the ALZAS-peptide but not against the Aβ-sequence. ELISA studies of plasma dectected highest titres of ALZAS in patients with mild cognitive impairment (presymptomatic AD), but only moderately increased titres in autopsy-confirmed AD, whereas low or undetectable ct-12 titres were found in cognitively intact age-matched subjects and young controls. The antigen, ALZAS protein, was detected in plasma in later clinical stages of AD. It is suggested that ALZAS represents an indicator in a dynamic equilibrium between both peripheral and brain degenerative changes in AD and may become a useful ‘non-invasive’ diagnostic marker via a simple blood test.
机译:迫切需要通过生物标志物早期检测退行性痴呆的简单,非侵入性测试。但是,到目前为止,尚无用于早期诊断阿尔茨海默病(AD)的经过验证的脑外诊断标志物(血浆/血清,血小板,尿液,结缔组织)。在具有明显认知障碍的疾病阶段,使用现代临床,神经心理学和影像学方法对可能的AD进行临床诊断的准确率约为90%。 CSF标记物,特别是tau和淀粉样蛋白β肽(Aβ)组合物和血浆标记物(例如Aβ-42/Aβ-40比)甚至可以改善疾病早期的诊断敏感性和特异性。最近,一种具有79个氨基酸序列的新型基因/蛋白质-ALZAS(ALZheimer关联蛋白),包含淀粉样蛋白β-42片段(Aβ-42),淀粉样蛋白前体蛋白(APP)跨膜信号和12个氨基酸C在APP区域内的21号染色体上发现了不存在于任何其他已知APP等位基因中的末端。逆转录-PCR显示该蛋白的转录本在人AD患者的皮质和海马区以及淋巴细胞中表达。 ALZAS的表达反映在AD患者中,是针对ALZAS肽的ct-12末端而不针对Aβ序列的特异性自身免疫反应。 ELISA研究发现轻度认知功能障碍(有症状的AD)患者血浆ALZAS最高滴度,但经尸检确认的AD滴度仅适度增加,而年龄完好的认知匹配受试者和年轻人中ct-12滴度较低或无法检测到控件。在AD的临床后期,血浆中检测到了抗原ALZAS蛋白。建议ALZAS代表AD周围性和大脑退行性变化之间动态平衡的指标,并可能通过简单的血液检查成为有用的“非侵入性”诊断标记。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号